Development and validation of an HPLC method with post-column derivatisation to assay n-acetylcysteine in plasma

• Autorzy: Vander Heyden Y. , Mangelings D. , Van Brempt J. , Spapen H.
• Języki publikacji: EN

Abstrakty

EN

A quantitative reversed-phase HPLC method has been developed that enables determination of both low endogenous and high therapeutic concentrations of N-acetylcysteine (NAC) in plasma. The compound is detected fluorimetrically after derivatisation with ortho-phthalaldehyde in the presence of a primary amine. Validation of the method revealed injection and method repeata-bility were good. The linear range was adequate and the limit of quantifi-cation was between 0.4 and 0.6 žM. Recovery of N-acetylcysteine from plasma samples was also acceptable. This method was applied to plasma samples from patients with a clinical septic shock who had received very high doses of N-acetylcys-teine. Six samples were taken at different times after administration of N-acetylcysteine. The blood-concentration profiles obtained indicate the me-thod is suitable for following the evolution of NAC in plasma under these conditions and can therefore be used for pharmacokinetic profiling.

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2004
• Tom: No. 14
• Strony: 149--164
• Opis fizyczny: Bibliogr. 23 poz., rys., tab.

Twórcy

autor

Vander Heyden Y.

• Dept. of Pharmaceutical and Biomedical Analysis, Pharmaceutical Institute, Vrije Universiteit Brussel-VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium

autor

Mangelings D.

• Dept. of Pharmaceutical and Biomedical Analysis, Pharmaceutical Institute, Vrije Universiteit Brussel-VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium

autor

Van Brempt J.

• Dept. of Pharmaceutical and Biomedical Analysis, Pharmaceutical Institute, Vrije Universiteit Brussel-VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium

autor

Spapen H.

• Dept. of Intensive Care, Academic Hospital, Vrije Universiteit Brussel, Brussels, Belgium

Bibliografia

• [1] K. Parfitt (Ed.) Martindale: The Complete Drug Reference, 32nd edition, Pharmaceutical Press, London, 1999, p. 1052
• [2] L.E. Schmidt, T.T. Knudsen, K. Dalhoff, and F. Bendtsen, Lancet, 360,1151 (2002)
• [3] F.V. Schiøt, P. Ott, E. Christensen, and S. Bondesen, Clin. Pharmacol. Ther., 71, 221 (2002)
• [4] L.E. Schmidt and K. Dallhoff, J. Clin. Pharmacol., 51, 87 (2001)
• [5] H.D. Spapen, D.N. Nguyen, K. ver Elst, Y. Vander Heyden, and L.P. Huyghens, Clin. Intensive Care, 13, 27 (2002)
• [6] H.F. Galley, P.D. Howdle, B.E. Walker, and N.R. Webster, Free Radical Biol. Med., 23, 768 (1997)
• [7] B. Olsson, M. Johansson, J. Gabrielsson, and P. Bolme, Eur. J. Clin. Pharmacol., 34, 77 (1988)
• [8] L. De Caro, A. Ghizzi, R. Costa, A. Longo, G.P. Ventresca, and E. Lodola, Drug Res., 39, 382 (1989)
• [9] M. Johansson and S. Lenngren, J. Chromatogr., 432, 65 (1988)
• [10] A. Stenken, D.L. Puckett, S.M. Lunte, and C.E. Lunte, J. Pharm. Biomed. Anal., 8, 85 (1990)
• [11] R. Gatti, V. Cavrini, P. Roveri, and S. Pinzauti, J. Chromatogr., 507, 451 (1990)
• [12] B. Kågedal, M. Källberg, and J. Mårtensson, J. Chromatogr., 331, 170 (1984)
• [13] M. Johansson and D. Westerlund, J. Chromatogr., 385, 343 (1987)
• [14] H. Nakamura and Z. Tamura, Anal. Chem., 53, 2190 (1981)
• [15] R.J. Kok, J. Visser, F. Moolenaar, D. de Zeeuw, and D.K.F. Meijer, J. Chromatogr. B, 693, 181 (1997)
• [16] A.I. Al-Amoud, B.J. Clark, and H. Chrystyn, J. Chromatogr. B, 769, 89 (2002)
• [17] C. Vannecke, S. Baré, M. Bloomfield, D.L. Massart, J. Pharm. Biomed. Anal., 18, 963 (1999)
• [18] C. Vannecke, E. Van Gyseghem, M.S. Bloomfield, T. Coomber, Y. Vander Heyden, and D.L. Massart, Anal. Chim. Acta, 446, 413 (2001)
• [19] C. Vannecke, M.S. Bloomfield, Y. Vander Heyden, and D.L. Massart, Anal. Chim. Acta, 455, 117 (2002)
• [20] P.A. Lewis, A.J. Woodward, and J. Maddock, J. Chromatogr., 327, 261 (1985)
• [21] D.L. Massart, B.G.M. Vandeginste, L.M.C. Buydens, S. De Jong, P.J. Lewi, and J. Smeyers-Verbeke, Handbook of Chemometrics and Qualimetrics: Part A, Elsevier, Amsterdam, 1997, p. 187
• [22] E. Chapuzet, N. Mercier, S. Bervoas-Martin, B. Boulanger, P. Chevalier, P. Chiap, D. Grandjean, P. Hubert, P. Lagorce, M. Lallier, M.C. Lapparra, M. Laurentie, and J.C. Nivet, S.T.P. Pharma Pratiques, 7, 169 (1997)
• [23] H. Spapen, Y. Vander Heyden, M. Diltoer, J. Ramet, L. Massart, and L. Huyghens, Am. J. Resp. Crit. Care, 157, A296 (1998)